Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Everolimus

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    07741_FLUKA

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 272,439Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Breckenridge Launches 1mg Everolimus Tablets, Generic Zortress
    Breckenridge Launches 1mg Everolimus Tablets, Generic Zortress

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/breckenridge-announces-launch-of-everolimus-tablets-1mg-generic-version-of-zortress-302599717.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    Sapu Nano to Present Sapu003 Data at SABCS 2025
    Sapu Nano to Present Sapu003 Data at SABCS 2025

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177142/0/en/Sapu-Nano-to-present-at-the-2025-San-Antonio-Breast-Cancer-Symposium-SABCS-Highlighting-Sapu003-Deciparticle-Everolimus.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    ITM Reveals Higher Response Rates Of (ITM-11) Vs. Everolimus
    ITM Reveals Higher Response Rates Of (ITM-11) Vs. Everolimus

    25 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/25/3174139/0/en/ITM-Announces-Analyses-from-Phase-3-COMPETE-Data-Showing-Higher-Objective-Response-Rates-with-n-c-a-177Lu-edotreotide-ITM-11-vs-Everolimus-Across-Subgroups-of-Patients-with-GEP-NET.html

    GLOBENEWSWIRE
    25 Oct 2025
    Share Share
    Oncotelic to Present Sapu003 Deciparticle Data at SABCS 2025
    Oncotelic to Present Sapu003 Deciparticle Data at SABCS 2025

    23 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/23/3171981/0/en/Oncotelic-to-present-at-the-2025-San-Antonio-Breast-Cancer-Symposium-SABCS-Highlighting-Sapu003-Deciparticle-Everolimus.html

    GLOBENEWSWIRE
    23 Oct 2025
    Share Share
    ITM’s Ph3 COMPETE Shows Higher ORR for ITM-11 vs Everolimus
    ITM’s Ph3 COMPETE Shows Higher ORR for ITM-11 vs Everolimus

    18 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/18/3168949/0/en/ITM-Announces-Phase-3-COMPETE-Data-Demonstrating-a-Statistically-Significant-Higher-Objective-Response-Rate-with-n-c-a-177Lu-edotreotide-ITM-11-vs-Everolimus-in-Patients-with-Gastr.html

    GLOBENEWSWIRE
    18 Oct 2025
    Share Share
    ESMO: Roche Wants Oral SERD To Benefit 'All Comers'
    ESMO: Roche Wants Oral SERD To Benefit 'All Comers'

    18 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-roche-wants-oral-serd-benefit-all-comers-unveils-phase-3-breast-cancer-data

    FIERCE BIOTECH
    18 Oct 2025
    Share Share